| Literature DB >> 28635645 |
Mohamed-Elamir F Hegazy1, Abdelsamed I Elshamy2, Tarik A Mohamed3, Ahmed R Hamed4,5, Mahmoud A A Ibrahim6, Shinji Ohta7, Paul W Paré8.
Abstract
Three new cembrene diterpenoids, sarcoehrenbergilid A-C (1-3), along with four known diterpenoids, sarcophine (4), (+)-7α,8β-dihydroxydeepoxysarcophine (5), sinulolide A (6), and sinulolide B (7), and one steroid, sardisterol (8), were isolated and characterized from a solvent extract of the Red Sea soft coral Sarcophyton ehrenbergi. Chemical structures were elucidated by NMR and MS analyses with absolute stereochemistry determined by X-ray analysis. Since these isolated cembrene diterpenes contained 10 or more carbons in a large flexible ring, conformer stabilities were examined based on density functional theory calculations. Anti-proliferative activities for 1-8 were evaluated against three human tumor cell lines of different origins including the: lung (A549), colon (Caco-2), and liver (HepG2). Sardisterol (8) was the most potent of the metabolites isolated with an IC50 of 27.3 µM against the A549 cell line. Since an elevated human-cancer occurrence is associated with an aberrant receptor function for the epidermal growth factor receptor (EGFR), molecular docking studies were used to examine preferential metabolite interactions/binding and probe the mode-of-action for metabolite-anti tumor activity.Entities:
Keywords: Sarcophyton ehrenbergi; cembranoids; cytotoxic activity; molecular docking; soft coral; terpenes
Mesh:
Substances:
Year: 2017 PMID: 28635645 PMCID: PMC5484142 DOI: 10.3390/md15060192
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Soft coral Sarcophyton ehrenbergi photographed in its native Red Sea habitat; the width of the species shown is ca. 20 cm.
1H and 13C NMR spectral data of 1–3 a.
| No. | 1 | 2 | 3 | |||
|---|---|---|---|---|---|---|
| δH | δC | δH | δC | δH | δC | |
| 1 | ------ | 164.3 | ------ | 164.6 | ------ | 164.4 |
| 2 | 5.50 d (10.1) | 81.0 | 5.49 dd (10.1; 1.8) | 81.7 | 5.51 br d (10.3) | 79.6 |
| 3 | 4.94 d (10.1) | 119.4 | 4.99 d (10.1) | 120.0 | 4.87 br d (10.3) | 117.8 |
| 4 | ------ | 141.6 | ------ | 142.6 | ------ | 146.0 |
| 5 | 2.07 t (13.1) 2.30 m | 40.9 | 2.17 br t (13.1) 2.47 dd (10.1; 13.1) | 38.8 | 2.09 br t (13.0) 2.41 br d (13.0) | 40.3 |
| 6 | 2.14 dd (6.8), 1.44 m | 27.6 | 1.66 m; 2.20 m | 22.9 | 1.88 m; 1.58 m | 24.9 |
| 7 | 3.24 d (6.9) | 78.5 | 3.44 dd (11.6; 3.6) | 69.7 | 3.01 br d (10.0) | 86.8 |
| 8 | ------ | 80.0 | ------ | 73.6 | ------ | 69.4 |
| 9 | 1.53 m; 1.91 m | 36.4 | 1.60 m; 2.40 m | 36.6 | 1.88 m; 2.41 br d (13.0) | 39.9 |
| 10 | 1.79 m; 2.15 m | 28.5 | 1.61 m; 1.90 m | 19.9 | 1.71 br d (10.9) 1.51 br t (10.9) | 23.1 |
| 11 | 3.37 m | 79.0 | 3.37 br d (11.9) | 85.1 | 3.30 br d (10.9) | 78.5 |
| 12 | ------ | 78.3 | ------ | 70.1 | ------ | 72.8 |
| 13 | 1.45 m; 2.37 m | 34.6 | 1.59 m 1.78 dd (12.5; 3.7) | 31.2 | 1.41 td (13.0; 5.8) 1.78 br t (13.0; 2.0) | 35.0 |
| 14 | 1.95 br t (12.2) 2.31 td (12.2, 7.0) | 20.8 | 2.00 br t (12.8) 2.58 td (12.8; 7.0) | 21.1 | 2.17 br t (13.0); 2.67 m | 21.1 |
| 15 | ------ | 122.3 | ------ | 122.3 | ------ | 122.5 |
| 16 | ------ | 175.9 | ------ | 176.0 | ------ | 175.6 |
| 17 | 1.76 s | 8.8 | 1.83 s | 8.7 | 1.82 s | 8.7 |
| 18 | 1.86 s | 17.0 | 1.92 br s | 16.7 | 1.85 br s | 16.1 |
| 19 | 1.05 s | 17.1 | 1.22 s | 22.1 | 1.15 s | 20.0 |
| 20 | 0.98 s | 17.6 | 1.13 s | 25.3 | 1.16 s | 23.8 |
| 21 | 3.13 s | 49.0 | ||||
J values (Hz) are in parentheses; a Recorded in CDCl3 and obtained at 600 and 150 MHz for 1H and 13C NMR, respectively.
Figure 2Structures of metabolites 1–8.
Figure 3Selected 1H-1H COSY (▬) and HMBC () correlations of 1–3.
Figure 4ORTEP depictions of cembrenoid 1 with oxygens (O1–O5) labeled in red.
Figure 5NOESY correlations for 1–3.
Figure 6Optimized confirmers for 1–3, as well as the next three higher free-energy conformers.
IC50 values * of tested compounds against A549, Caco-2, and HepG2 cells.
| Compound | A549 IC50(µM) | Caco-2 IC50(µM) | HepG2 IC50(µM) |
|---|---|---|---|
| 1 | 50.1 | >100 | 98.6 |
| 2 | 76.4 | >100 | >100 |
| 3 | 50.8 | >100 | 53.8 |
| 4 | 91.5 | >100 | >100 |
| 5 | 62.2 | >100 | 79.3 |
| 6 | 37.0 | 79.2 | 70.2 |
| 7 | 43.6 | 99.2 | 63.1 |
| 8 | 27.3 | >100 | 56.8 |
| Doxorubicin HCl | 0.62 | 1.40 | 2.10 |
* IC50 values were obtained by fitting the concentration-response curve to non-linear regression. model on GraphPad ®Prism software v 6.0.
Figure 7Crystal structure (in cyan) and predicted docking pose (in pink) of (a) erlotinib; (b) afatinib; and (c) gefitinib; and AMBER-based minimized docked structures of (d) doxorubicin; (e) 8; (f) 7; (g) 6; and (h) 4 with EGFR kinase domain (PDB code: 1M17).